RxDoctor Payments Data

Kimberly Cai

Internal Medicine · Hackensack, NJNPI 1679967103

Payments from drug & device makers

$8,691in general payments, 2019–2025

Across 276 payments — averaging $31.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Novo Nordisk$1K
  • AstraZeneca$652
  • Lilly USA, LLC$270
  • Daiichi Sankyo Inc.$229
  • Exact Sciences$219
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$4,58153%
  • Food & beverage$4,04146%
  • Education$691%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,691 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$78,678
Medicare patients
177
Services billed
708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin58$92,810
OzempicSemaglutide41$65,248
FarxigaDapagliflozin Propanediol45$42,452
JanuviaSitagliptin Phosphate17$27,942
MounjaroTirzepatide11$24,077
XareltoRivaroxaban27$23,570
Tresiba Flextouch U-200Insulin Degludec18$20,649
Soliqua 100-33Insulin Glargine/Lixisenatide12$16,922
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,766
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,034
Novolog FlexpenInsulin Aspart18$9,013
TradjentaLinagliptin13$7,210
Atorvastatin Calcium304$4,420
Advair DiskusFluticasone Propion/Salmeterol11$2,631
Rosuvastatin Calcium90$1,826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$128$100,02071 claims
Novo NordiskOzempic$1,432$65,24841 claims
AstraZenecaFarxiga, Breztri Aerosphere$652$55,48666 claims
MerckJanuvia$67$27,94217 claims
Lilly USA, LLCMounjaro$270$24,07711 claims
Johnson & JohnsonXarelto$68$23,57027 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$97$16,92212 claims
GSKTrelegy Ellipta$202$13,76614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →